Using Cognitive Assessment to Improve Decision Making in Oncology Clinical Trials

Using Cognitive Assessment to Improve Decision Making in Oncology Clinical Trials


March 10, 2021 at 1 PM EST


In the oncology field, there is growing interest in using patient-centered clinical outcome assessments (COAs) in clinical research to determine the potential benefits and safety of new and existing treatments as well as their effects on level of overall function. As such, clinical trial teams are now leveraging digital technologies, including patient-reported and performance-based assessments, to answer important questions about these therapeutics.

In this webinar, presenters will discuss the collection of digital endpoints relevant to oncology that can improve signal detection and gather relevant data needed to measure treatment response.

Webinar participants will gain a greater understanding of:

  • The assessment of cognition and function in people with cancer entering clinical trials – the application of subjective (PRO) and objective (PerfO) measures
  • Leveraging digital technologies to drive sensitive, reliable, and efficient measurements
  • Statistical and methodological issues associated with identification of treatment related cognitive dysfunction 
  • Recent regulatory guidance and implications for trial conduct
  • Remote assessment considerations for decentralized trials
  • Case examples from pediatric and adult indications, including immuno-oncology

FEATURED GUESTS


Kelly Dumais, PhD, Clinical Scientific Advisor, ERT


Kelly Dumais, PhD

Clinical Scientific Advisor
ERT

Dr. Dumais is a neuroscientist with 8 years of experience in the design and management of neuroscience research. She has extensive experience in electronic clinical outcome assessments (eCOA) and the development and validation of patient reported outcomes (PROs) to support labeling claims. She consults on best practices for questionnaire design and eCOA design/use. Kelly develops custom site rater training for improving inter-rater reliability, and develops custom patient training for improving accuracy in PRO reporting and patient engagement. She has co-authored book chapters and over a dozen manuscripts, and has presented her work at national and international meetings. Dr. Dumais completed her doctoral training in Psychology- Neuroscience from Boston College and completed her Postdoctoral Fellowship at McLean Hospital – Harvard Medical School.

Paul Maruff, PhD

Chief Innovation Officer
Cogstate

Professor Paul Maruff is one of the founders of Cogstate and served as Chief Science Officer before taking on the role of Chief Innovation Officer. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to guide decision making in drug development and in clinical medicine. Paul remains an active researcher. He is appointed Professor at the Florey Institute for Neuroscience and Mental Health. He is currently clinical co-chair of the Australian Imaging Biomakers and Lifestyle (AIBL) study. Paul has published over 450 research articles in international peer-reviewed scientific journals and has co-authored 15 book chapters.